Pyxis Oncology (NASDAQ:PYXS – Get Free Report) was upgraded by equities research analysts at William Blair from a “market perform” rating to an “outperform” rating in a note issued to investors on Friday, Marketbeat Ratings reports.
Other equities analysts have also issued research reports about the stock. Royal Bank Of Canada lifted their price target on shares of Pyxis Oncology from $6.00 to $7.00 and gave the company an “outperform” rating in a report on Friday, November 6th. Wall Street Zen upgraded Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Wells Fargo & Company upped their target price on Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 9th. Stifel Nicolaus set a $5.00 target price on shares of Pyxis Oncology in a research note on Thursday, November 5th. Finally, Wedbush dropped their price target on shares of Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating on the stock in a research note on Friday, November 6th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.71.
Get Our Latest Stock Report on PYXS
Pyxis Oncology Stock Performance
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03. As a group, sell-side analysts expect that Pyxis Oncology will post -1.12 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pyxis Oncology
A number of hedge funds have recently bought and sold shares of PYXS. Renaissance Technologies LLC increased its holdings in Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after purchasing an additional 160,300 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Pyxis Oncology by 221.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 147,598 shares of the company’s stock valued at $344,000 after purchasing an additional 101,698 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Pyxis Oncology in the 3rd quarter valued at approximately $219,000. Jump Financial LLC acquired a new position in shares of Pyxis Oncology in the 3rd quarter valued at approximately $150,000. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Pyxis Oncology by 14.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock valued at $114,000 after buying an additional 6,295 shares during the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
Further Reading
- Five stocks we like better than Pyxis Oncology
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
